KBLB · Kraig Biocraft Laboratories, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $66.7K | - | $9.2K | $63.9K | $23.9K | - | $25.0K | $49.4K | $29.4K | - |
| SG&A | $495.6K | - | $1.20M | $344.0K | $308.9K | - | $205.3K | $1.10M | $164.4K | - |
| Total Operating Expenses | $825.5K | - | $1.43M | $637.7K | $580.5K | - | $423.8K | $1.49M | $448.7K | - |
| D&A | $6.2K | - | $6.0K | $5.8K | $5.7K | - | $6.6K | $6.7K | $6.7K | - |
| Operating Income | ($825.5K) | - | ($1.43M) | ($637.7K) | ($580.5K) | - | ($423.8K) | ($1.49M) | ($448.7K) | - |
| Interest Expense | $148.4K | - | $144.3K | $130.9K | $129.9K | - | $122.0K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($942.7K) | - | ($1.51M) | ($726.1K) | ($600.0K) | - | ($433.2K) | ($1.61M) | ($507.9K) | - |
| EPS - Basic | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.89M | $1.79M | $1.57M | $785.5K | $397.0K | $673.3K | $1.19M | $1.52M | $2.05M | $2.55M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $74.3K | $29.1K | $29.1K | $6.9K | $6.9K | $6.9K | $6.9K | $6.9K | $6.9K | $6.9K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $3.01M | $1.87M | $1.64M | $839.0K | $452.7K | $740.3K | $1.24M | $1.53M | $2.06M | $2.57M |
| Total Assets | $3.72M | $2.57M | $2.36M | $1.59M | $1.32M | $1.51M | $2.03M | $2.22M | $2.77M | $3.23M |
| Current Liabilities | $10.68M | $10.45M | $10.18M | $10.03M | $9.83M | $9.61M | $9.34M | $9.15M | $8.96M | $8.89M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.78M | $10.56M | $10.31M | $10.06M | $9.86M | $9.65M | $9.38M | $9.19M | $9.01M | $8.94M |
| Stockholders' Equity | ($7.06M) | ($8.00M) | ($7.96M) | ($8.47M) | ($8.55M) | ($8.15M) | ($7.36M) | ($6.97M) | ($6.24M) | ($5.71M) |
| Retained Earnings | ($57.65M) | ($56.71M) | ($55.92M) | ($54.41M) | ($53.69M) | ($53.09M) | ($52.23M) | ($51.80M) | ($50.19M) | ($49.69M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($529.7K) | - | - | - | ($434.5K) | - | - | - | ($489.5K) | - |
| Investing Cash Flow | ($14.1K) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $1.64M | - | - | - | $158.2K | - | - | - | ($15.0K) | - |
| CapEx | $14.1K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($543.8K) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.58 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.3% | - | -64.1% | -45.6% | -45.6% | - | -21.4% | -72.4% | -18.3% | - |
| Return on equity | 13.3% | - | 19.0% | 8.6% | 7.0% | - | 5.9% | 23.0% | 8.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.28 | 0.18 | 0.16 | 0.08 | 0.05 | 0.08 | 0.13 | 0.17 | 0.23 | 0.29 |
| Quick ratio | 0.27 | 0.18 | 0.16 | 0.08 | 0.05 | 0.08 | 0.13 | 0.17 | 0.23 | 0.29 |
| Cash ratio | 0.27 | 0.17 | 0.15 | 0.08 | 0.04 | 0.07 | 0.13 | 0.17 | 0.23 | 0.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.6x | - | -9.9x | -4.9x | -4.5x | - | -3.5x | - | - | - |
| Equity multiplier | -0.53 | -0.32 | -0.30 | -0.19 | -0.15 | -0.18 | -0.28 | -0.32 | -0.44 | -0.57 |
| Liabilities / Assets | 2.90 | 4.12 | 4.38 | 6.32 | 7.50 | 6.41 | 4.63 | 4.14 | 3.25 | 2.77 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -42.2% | - | -238.3% | 57.1% | -29.4% | - | 7.8% | -209.2% | 7.8% | - |
| Net income growth (YoY) | -57.1% | - | -248.5% | 54.8% | -18.1% | - | 21.1% | -172.7% | 10.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 17.4% | 1.8% | -8.1% | -21.5% | -36.9% | -42.8% | -47.2% | -54.6% | -54.6% | -62.0% |
Peer comparison
Same SIC group: Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)
Comparing Kraig Biocraft Laboratories against the 2 most active filers in the same SIC group.